Group 1 - Viatris Inc. is a global healthcare company formed from the merger of Mylan and Pfizer's Upjohn division in 2020, operating in over 165 countries and focusing on both generics and specialty pharmaceuticals [2] - The FDA approval of Viatris's first generic iron sucrose injection, a version of Venofer, is a significant development, with annual U.S. sales of approximately $515 million, marking an entry into the intravenous iron market [3] - Positive late-stage trial results for several pipeline assets, including fast-acting meloxicam for acute pain and the next-generation birth control patch XULANE LO, support the company's growth strategy and upcoming product launches through 2026 [4] Group 2 - Viatris's strategic emphasis on complex generics and specialty products indicates a shift from a primarily generic-focused business to a more innovation-driven company, highlighting the resilience of its diversified portfolio [5]